Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.22) by 0.82 percent. This is a 11.51 percent increase over losses of $(1.39) per share from the same period last year.